All posts by medical

BRIEF-Seattle Genetics Announces Cancellation Of Presentation And Webcast At The Cowen 40th Annual Healthcare Conference – Reuters

March 2 (Reuters) - Seattle Genetics Inc:

* SEATTLE GENETICS ANNOUNCES CANCELLATION OF PRESENTATION AND WEBCAST AT THE COWEN 40TH ANNUAL HEALTHCARE CONFERENCE

* SEATTLE GENETICS - WILL NO LONGER BE ATTENDING CONFERENCE AS A PRECAUTIONARY MEASURE RELATED TO TRAVEL AMIDST EVOLVING CORONAVIRUS SITUATION Source text for Eikon: Further company coverage:

See more here:
BRIEF-Seattle Genetics Announces Cancellation Of Presentation And Webcast At The Cowen 40th Annual Healthcare Conference - Reuters

Researchers dive deep into the genetic legacy of the transatlantic slave trade – ZME Science

Print showing an alleged incident of an enslaved African girl whipped to death for refusing to dance naked on the deck of the slave shipRecovery, a slaver owned by Bristol merchants. Captain John Kimber was denounced before the House of Commons by William Wilberforce over the incident. In response to outrage by abolitionists, Captain Kimber was brought up on charges before the High Court of Admiralty in June 1792, but acquitted of all charges. Credit: United States Library of Congresss Prints and Photographs division.

Researchers in Brazil combined historical and genetic data to reveal new insights about the transatlantic slave trade that saw more than 9 million Africans shipped in chains to the Americans from the early 16th century until the mid-19th century. The findings suggest that the African populations imported their genetic diversity and spread their mutations in the Americas through admixture with indigenous and European populations.

We know in the Americas that the slave trade was a human tragedy, but it is part of our history and identity. This is why my group, but mainly myself and my former PhD student Mateus Gouveia focused in the African Diaspora, Eduardo Tarazona-Santos, a researcher at the Federal University of Minas Gerais in Brazil and lead author of the new study, told ZME Science.

African populations are the most diverse in the world, genetically speaking. Tarazona worked closely with colleagues in Brazil, Peru, and the United States to assemble what he calls the largest up-to-date dataset of Americas and African genetic data, which includes 6,267 individuals with more than 10% African ancestry from 25 populations.

Researchers compared the genetic data with historical demographic data from Slave Voyages database, which tracked and mapped the dispersal of enslaved Africa into the Americas.

We came out with a mathematical method that makes this comparison compatible. Then werealizedthat comparing genetic and historical-demography data is something modern geneticists had forgotten to do during the last 10-20 years, but it this kind of comparisons were more common before and have a solid tradition in human population genetics, since thework by Luca Cavalli-Sforza (who passed away in 2018) sixtyyears ago in the Parma Valley in Italy, where he compared genetic data (from blood groups) with parish record data. So recovering this kind of work, is like making a tribute to Luca Cavalli-Sforza. Reading his books has been an inspiration for many young investigators that in the nineties decided to dedicate to human population genetics, as I did, Tarazona said.

The researchers found that West Central African ancestry (from countries such as Nigeria and Ghana) is the most common in the Americas. West African ancestry (i.e. Senegal and Gambia) increases going northward while bantu ancestry (from south and southeast Africa) is more significant in the South of Brazil.

Historical records show that the transatlantic slave trade was at its height between 1750 and 1850. The new study found that this period also coincides with the most admixture between imported African populations and locals of European and indigenous ancestry. This timing implies that the 19th century was critical in shaping the structure of the African gene pool in the New World.

The African Diaspora was so massive (>9 million people), that the genetic diversity observed in the African portions of our admixed genomes is similar to that of African populations of origin of slavery. However, admixture homogenized this diversity (and the mutations responsible for diseases) between the different populations of the African continent, Tarazona told ZME.

All in all, the study provides unique insights into the gene flow caused by the massive transatlantic slave trade, whose influence is still important in todays social and cultural setting in the Americas.

Our results imply that the Africans imported most of their genetic diversity, including the mutations responsible for the diseases, and that admixture has spread these mutations in the Americas along most of the continent. In Africa, they are more compartmentalized geographically. This is important when we interpret data about where there are in the Americas mutations responsible for diseases such as cystic fibrosis and hereditary cancer, Tarazona concluded.

The findings appeared on March 2 in the journal Molecular Biology and Evolution.

More:
Researchers dive deep into the genetic legacy of the transatlantic slave trade - ZME Science

Riding the Trend or Protecting Profits: Seattle Genetics, Inc. (SGEN) – The News Heater

Seattle Genetics, Inc. (NASDAQ:SGEN) went down by -1.74% from its latest closing price when compared to the 1-year high value of $124.32 and move down -11.12%, while SGEN stocks collected -3.55% of loss with the last five trading sessions. Press Release reported 15 hours ago that Seattle Genetics Announces Cancellation of Presentation and Webcast at the Cowen 40(th) Annual Healthcare Conference

Seattle Genetics, Inc. (NASDAQ: SGEN) The 36 Months beta value for SGEN stocks is at 1.80, while of the analysts out of 0 who provided ratings for Seattle Genetics, Inc. stocks as a buy while as overweight, rated it as hold and as sell. The average price we get from analysts is $127.80 which is $13.87 above current price. SGEN currently has a short float of 2.91% and public float of 170.23 M with average trading volume of 1.10M shares.

SGEN stocks went down by -3.55% for the week, with the monthly jump of 1.83% and a quarterly performance of -7.55%, while its annual performance rate touched 49.81%. The simple moving average for the period of the last 20 days is -3.12% for SGEN stocks with the simple moving average of 22.98% for the last 200 days.

Many brokerage firms have already submitted their reports for SGEN stocks, with Barclays repeating the rating for SGEN shares by setting it to Equal Weight. The predicted price for SGEN socks in the upcoming period according to Barclays is $124 based on the research report published on February 18, 2020.

H.C. Wainwright, on the other hand, stated in their research note that they expect to see SGEN stock at the price of $150, previously predicting the value of $140. The rating they have provided for SGEN stocks is Buy according to the report published on February 12, 2020.

Goldman gave Buy rating to SGEN stocks, setting the target price at $165 in the report published on February 11, 2020.

After a stumble in the market that brought SGEN to its low price for the period of the last 52 weeks, Seattle Genetics, Inc. was unable to take a rebound, for now settling with -10.01% of loss for the given period.

The stock volatility was left at 4.45%, however, within the period of a single month, the volatility rate increased by 7.09%, while the shares surge at the distance of +3.22% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by -1.17% lower at the present time.

In the course of the last 5 trading sessions, SGEN went down by -3.55%, which changed the moving average for the period of 200 days to the total of +74.84% of gains for the stock in comparison to the 20-day moving average settled at $115.65. In addition, Seattle Genetics, Inc. saw -2.08% in overturn over the period of a single year with a tendency to cut further losses.

Reports are indicating that there were more than several insider trading activities at Seattle Genetics, Inc. (SGEN), starting from DANSEY ROGER D, who sold 350 shares at the price of $116.33 back on Feb 18. After this action, Rushing now owns 107,659 shares of Seattle Genetics, Inc., valued at $40,716 with the latest closing price.

SIEGALL CLAY B, the President and CEO of Seattle Genetics, Inc., sold 28,472 shares at the value of $114.61 during a trade that took place back on Feb 10, which means that SIEGALL CLAY B is holding 758,784 shares at the value of $3,263,110 based on the most recent closing price.

The current profitability levels are settled at -24.06 for the present operating margin and +95.21 for gross margin. The net margin for Seattle Genetics, Inc. stands at -17.31. Total capital return value is set at -13.67, while invested capital returns managed to touch -9.86. Equity return holds the value -10.20%, with -8.50% for asset returns.

Based on Seattle Genetics, Inc. (SGEN), the companys capital structure generated 4.11 points for debt to equity in total, while total debt to capital is set at the value of 3.94.

The value for Enterprise to Sales is 21.39 with debt to enterprise value settled at 0.00. The receivables turnover for Seattle Genetics, Inc. is 4.80 with the total asset turnover at the value of 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.54.

See the article here:
Riding the Trend or Protecting Profits: Seattle Genetics, Inc. (SGEN) - The News Heater

#ExtendTheLimit of what PET can do – BioNews

2 March 2020

Changing the law is a central part of what the Progress Educational Trust (PET) does. PET was born out of a campaign the Progress Campaign for Research into Human Reproduction and more than 30 years later, remains actively involved in several campaigns. It is in our DNA to campaign on your behalf.

I remember when I started at PET over a decade ago, I went to a meeting on my first day to discuss the reform of the Human Fertilisation and Embryology (HFE) Act 1990. There in the Houses of Parliament with the Department of Health (as it was called then), the Wellcome Trust, the Royal Society and the Medical Research Council sat PET firmly in the centre of things.

PET has remained in the centre of things ever since: Campaigning for the law change to permit mitochondrial donation to give women the chance of avoiding passing on mitochondrial disease to their children Working with others to get surrogacy law reform on the Government's agenda Fighting for better access to NHS funded fertility treatment

The list goes on.

With our 2018 conference 'Make Do or Amend: Should We Update UK Fertility and Embryo Law?', a specific aim was to put reviewing the 1990 and 2008 HFE Acts on the Department of Health and Social Care (DHSC)'s agenda.

This objective was met, and PET and other organisations (including Wellcome) were contacted by DHSC to discuss what the priorities for change should be. These talks are on-going and if there is one thing I have learned when it comes to law reform, it is that persistence pays.

Our latest campaign, #ExtendTheLimit has had a huge impact. A year ago, the then Minister was not interested in even contemplating a change but undeterred we continued to push and launched our campaign in October 2019. Since then the DHSC has launched a consultation and just this week the Royal College of Obstetricians and Gynaecologists published a scientific impact paper entitled 'Elective Egg Freezing for Non-Medical Reasons' and together with the British Fertility Society have backed PET's calls for extending the time women can freeze their eggs to delay having a baby (see BioNews 1037).

PET's petition enabling you to show your support for #ExtendTheLimit will be relaunched just as soon as the Government's petitions committee is up and running. Patience is also an important part of campaigning as we can't always dictate the pace!

Our policy work is funded by donations and the Friends of PET scheme and we need your financial support if we are going to continue to fight to improve reproductive choice.

We need your help.

Please donate to our #ExtendTheLimit appeal here. Or better still become a Friend of PET so we can #ExtendTheLimit of what we can do.

More here:
#ExtendTheLimit of what PET can do - BioNews

In Vitro Fertilization Market 2020: Industry Analysis and Detailed Profiles of Top Industry Players AMP Center St Roch, AVA International Clinic…

Global In Vitro Fertilization Market,By Product (Reagents, Equipment),Type of Cycle (Fresh Non-Donor IVF Cycles, Frozen Non-Donor IVF Cycles, Frozen Donor IVF Cycles, Fresh Donor IVF Cycles), End User (Hospitals & Research Laboratories, Cryobanks ),Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2025

Global In Vitro Fertilization Market is expected to reach USD 847.8 billion by 2025, from USD 465.2 billion in 2017 growing at a CAGR of 10.0 % during the forecast period of 2018 to 2025. The upcoming market report contains data for the historic year 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Major Market Competitors/Players:

Some of the major players operating in global in- vitro fertilization market are Groupe Clinique Ambroise Par, amedes MVZ Cologne GmbH, AMP Center St Roch, AVA International Clinic Scanfert, Bangkok IVF center, Betamedics, Biofertility Center, Bloom Healthcare, Bourn Hall Fertility Center, , Cardone & Associates Reproductive Medicine & Infertility, The Center for Advanced Reproductive Services, Chelsea and Westminster Hospital NHS Foundation Trust, Cloudnine Fertility, Conceptions Reproductive Associates of Colorado, Cyprus IVF Centre, Dansk Fertilitetsklinik, EUVITRO S.L.U., , Lieff Cabraser Heimann & Bernstein, LLP, Fertility First, IVF Centers Prof. Zech, Flinders Reproductive Medicine Pty Ltd, Genea Oxford Fertility Limited, IVF Spain, IVI Panama, KL Fertility & Gynaecology Centre, Lifesure Fertility and Gynaecology centre, Manipal Fertility, , Medfem Fertility Clinic, Monash IVF, OVA IVF Clinic Zurich, Procrea, RAPRUI S.r.l., SAFE FERTILITY CENTER, SANNO HOSPITAL, SIRM Fertility Clinics, Stork IVF Klinik, ARC-STER S.r.l., The Montreal Fertility Center, Thomson Medical Centre, TRIO Fertility, Virtus Health, VivaNeo, Die Kinderwunsch and among others.

Competitive Analysis:

The global In- Vitro Fertilization market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of In- Vitro Fertilization market for global, Europe, North America, Asia Pacific and South America.

Market Definition:

In vitro fertilization is a procedure in which egg from women ovary are removed and after that the egg is fertilized with a sperm in a laboratory procedure, and then the fertilized egg is transfered into the women uterus. In vitro fertilization is used in the management of female infertility. In 2018, the Cooper Companies was announce that the Cooper Surgical acquired the assets of The Life Global Group and its affiliates which is a leading provider of invitrofertilization devices. In July 2018, Merck launched new product Geri Assess 2.0.This product is useful in automatic detection of embryo and blastocyst development, improving efficiency in assessment.

According to the Centre for Disease Control and Prevention in 2016, approximately 263,577 ART (Assisted Reproductive Technology) cycle was performed in US. As per the Human Fertilization and Embryology Authority in 2016, more than 68,000 IVF treatments were provided in U.K. In 2016 Birth rate from IVF has been increased to 85.0% in U.K. In 2016 around 20000 childrens were born by IVF. As per the published news IVF Success Rates For Fertility Clinics in the United States in 2016 and around 263,577 ART cycle was performed in U.S. Due to the increasing rate of infertility amongst the population, patients are opting the IVF Fertilization which is fuelling the growth of market.

Major Market Drivers and Restraints:

Market Segmentation:

The global In vitro fertilization market is segmented based on product, type of cycle, end user and geographical segments.

Based on product, the market is segmented into reagents, equipment.

Based on reagents, the market is further segmented into embryo culture media, cryopreservation media, sperm processing media, OVUM processing media.

Based on equipment, the market is further segmented into imaging systems, sperm separation systems, cabinets, OVUM aspiration pumps, incubators, micromanipulator systems, gas analysers, laser systems, accessories, cryo systems, anti-vibration tables, witness systems.

Based on type of cycle, the market is segmented into fresh non-donor IVF cycles, frozen non-donor IVF cycles, frozen donor IVF cycles, fresh donor IVF cycles.

Based on end user, the market is segmented into fertility clinics & surgical centers, hospitals & research laboratories, cryobanks.

Based on geography, the market report covers data points for 28 countries across multiple geographies namely North America & South America, Europe, Asia-Pacific and, Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa and, Brazil among others

Key Developments in the Market:

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email:[emailprotected]

Read this article:
In Vitro Fertilization Market 2020: Industry Analysis and Detailed Profiles of Top Industry Players AMP Center St Roch, AVA International Clinic...

BioXcel Therapeutics to Host Fourth Quarter and Full Year 2019 Operating and Financial Results Conference Call and Webcast – Yahoo Finance

NEW HAVEN, Conn., March 02, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (BTI or Company) (BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced it will host a conference call and webcast on Monday, March 9, 2020 at 8:30 AM Eastern Time to discuss its fourth quarter and full year 2019 operating and financial results.

Conference Call & Webcast Details

Date/Time: Monday, March 9, 2020, 8:30 AM Eastern TimeDomestic: 877-407-2985International: 201-378-4915

The webcast will be accessible* under "Events" on the News & Media page of the Company's website at http://www.bioxceltherapeutics.com.

ReplayDomestic: 877-660-6853International: 201-612-7415Conference ID: 13696573

*Replay available through March 23, 2020

About BioXcel Therapeutics, Inc.:

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, an investigational sublingual thin film formulation in development for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an investigational orally administered systemic innate immunity activator in development for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer in combination with other immuno-oncology agents. For more information, please visit http://www.bioxceltherapeutics.com.

Contact Information:

BioXcel Therapeutics, Inc.www.bioxceltherapeutics.com

Investor Relations: John Graziano jgraziano@troutgroup.com1.646.378.2942

Media: Julia Deutsch jdeutsch@troutgroup.com1.646.378.2967

Original post:
BioXcel Therapeutics to Host Fourth Quarter and Full Year 2019 Operating and Financial Results Conference Call and Webcast - Yahoo Finance

Sponsored | How a Neurobiologist and a Biotech Manager Turned Their Passion for Science into Teaching – BioSpace

Step into Antioch High Schools senior biotech class, and you will see experiments that use DNA extraction, polymerase chain reaction and gel electrophoresis. At a high-needs school where over 70% of students qualify for free or reduced price lunch, this is not your typical high school lab equipment or techniques. Not your typical low-income high school lab equipment. But thats par for the course when your high school biology teacher has a PhD in neuroscience and over a decade of lab experience.

David House made the transition from post-doctoral research in Geneva, Switzerland, to inspiring students as a biotech teacher in the San Francisco Bay Area, with the help of EnCorps STEM Teachers Program. After spending 14 years in research labs, David decided it was time to leave the lab. He explored many options like programming and engineering, but realized teaching would allow him to share his passion for science in a new and meaningful way.

To make the transition to teaching, David relied on EnCorps STEM Teachers Program. He was able to spend a semester in a local high school under the mentorship of earth science teacher, Adam Siegel. His on-the-ground experience was complemented by online training, in-person practical sessions with other STEM-professionals-turned-teachers in the Bay Area, and networking with his cohort of 113 STEM Teaching Fellows across California.

David says, Teaching students in disadvantaged communities has been a chance to use my background in science to help improve opportunities for kids that really need it. Plus, theres a new focus on preparing students to understand and solve real-world problems using science and engineering practices. I feel as if having experience in the sciences has been incredibly valuable for connecting students to how science makes a difference in peoples lives.

With a background in corporate research and product development, EnCorps STEM Teaching Fellow Don Selway found that teaching met his desire to give back. Don teaches biology at SOUL Charter School in San Diego, where his students engage in experiential and project-based learning. He knows that interdisciplinary skills like collaboration and teamwork are priorities for advancing a scientific career. With his unique expertise and experience as a program manager for cell therapy new product development, he connects classroom learning to potential future careers for his students, many of whom had never met anyone from the biotech industry before.

Don says, EnCorps was amazing in guiding me through the pathway to earn a teaching credential. Ive made several close friends in my cohort that I call upon when I have challenges in my classroom.

California-based EnCorps STEM Teachers Program transitions professionals from science, technology, engineering and math (STEM) industries into careers as middle and high school teachers in under-resourced schools. The organization was founded to alleviate the nationwide teacher shortage that disproportionately impacts low income schools, with the ultimate goal to prepare the future STEM workforce with an excellent educational foundation. Statewide Recruitment Director, Bethany Orozco, says STEM professionals are uniquely positioned to teach in science and math classrooms because students want to know how their education is applicable to their real life. EnCorps Teaching Fellows engage students with stories of their first hand experience in careers like manufacturing, scientific research and programming.

EnCorps Teaching Fellows begin their role by guest teaching in a local classroom with a mentor teacher, where they gain valuable teaching insight, learn to build relationships and inspire adolescents. Fellows engage in online and in-person training, networking and then teach at EnCorps partner schools - both district and charter - across Los Angeles, San Francisco Bay Area, Sacramento, Riverside, North Orange County and San Diego. Since 2007, EnCorps has selected more than 1,000 Teaching Fellows to make the transition. The selection process is rigorous and that number represents about 13% of all applicants.

For professionals considering a career change to teaching, Orozco, a former high school math and science teacher herself, says it can be incredibly rewarding. EnCorps Teachers will, on average, impact over 1,200 students if they teach for just 10 years. The professional development and support EnCorps provides helps teachers meet that milestone. This type of impact can have an exponential effect, and ultimately serves industry by preparing hundreds of students to enter the STEM workforce. Lastly - Orozco says it is most important for prospective EnCorps Teachers to believe that all students can succeed when given the right opportunities, regardless of background.

Even if just one student follows in the footsteps of an EnCorps Fellow, teaching can be an incredibly rewarding career. EnCorps Teacher Julian Lewis not only connects his students to real-world applications of math and science in his aerospace engineering classroom, but he also inspired one student to pursue an education at his alma mater, Embry Riddle Aeronautical University. A former Lockheed Martin aerospace engineer of 34 years, Lewis grew up in the South Bronx and was inspired by an eighth grade teacher who was a pilot. He says that the satisfaction of working on amazing aircraft equals the satisfaction he gets from watching his students become engaged in aerospace. At the end of the day, whats going to be your legacy? What have you impacted? As I share my experience, they are realizing they too can do that.

To learn more about the EnCorps STEM Teachers Program, visit http://www.encorps.org.

Go here to see the original:
Sponsored | How a Neurobiologist and a Biotech Manager Turned Their Passion for Science into Teaching - BioSpace

Could This Robot Help Children With Autism Learn? – Technology Networks

Many children with autism face developmental delays, including communication and behavioral challenges and difficulties with social interaction. This makes learning new skills a major challenge, especially in traditional school environments.Previous research suggests socially assistive robots can help children with autism learn. But these therapeutic interventions work best if the robot can accurately interpret the childs behavior and react appropriately.

Now, researchers at USCs Department of Computer Science have developed personalized learning robots for children with autism. They also studied whether the robots could estimate a childs interest in a task using machine learning.

In one of the largest studies of its kind, the researchers placed a socially assistive robot in the homes of 17 children with autism for one month. The robots personalized their instruction and feedback to each childs unique learning patterns during the interventions.

After the study was completed, the researchers also analyzed seven of the participants engagement and determined the robot could have autonomously detected whether or not the child was engaged with 90% accuracy.Making robots smarter

Robots are limited in their ability to autonomously recognize and respond to behavioral cues, especially in atypical users and real-world environments. This study is the first to model the learning patterns and engagement of children with autism in a long-term, in-home setting.Current robotic systems are very rigid, said lead author Shomik Jain, a progressive degree mathematics student advised by socially assistive robotics pioneer Professor Maja Matari.

If you think of a real learning environment, the teacher is going to learn things about the child, and the child will learn things from them. Its a bidirectional process and that doesnt happen with current robotic systems. This study aims to make robots smarter by understanding the childs behavior and responding to it in real- time.

The researchers stress the goal is to augment human therapy, not replace it.

Human therapists are crucial, but they may not always be available or affordable for families, said Kartik Mahajan, an undergraduate student in computer science and study co-author. Thats where socially assistive robots like this come in.Enhancing the learning experienceFunded by a National Science Foundation (NSF) grant given to Matari, the research team placed Kiwi the robot in the homes of 17 children with autism spectrum disorders for about a month. The child participants were all aged between 3 and 7 and from the greater Los Angeles area.

During almost daily interventions, the children played space-themed math games on a tablet while Kiwi, a 2-foot tall robot dressed like a green feathered bird, provided instruction and feedback.

Kiwis feedback and the games difficulty were personalized in real-time according to each childs unique learning patterns. Mataris team in the USC Interaction Lab accomplished this using reinforcement learning, a rapidly growing subfield of artificial intelligence (AI).

The algorithms monitored the childs performance on the math games. For instance, if a child answered correctly, Kiwi would say something like, Good job!. If they got a question wrong, Kiwi might give them some helpful tips to solve the problem, and adjust the difficulty and feedback in future games. The goal was to maximize difficulty, while also not pushing the learner to make too many mistakes.

If you have no idea what the childs ability level is, you just throw a bunch of varying problems at them and its not good for their engagement or learning, said Jain.

But if the robot is able to find an appropriate level of difficulty for the problems, then that can really enhance the learning experience.The ultimate frontierTheres a popular saying among people with autism and their families: If you have met one person with autism, you have met one person with autism.

Autism is the ultimate frontier for robotic personalization, because as anyone who knows about autism will tell you, every individual has a constellation of symptoms and different severities of each symptom, said Matari, Chan Soon-Shiong Distinguished Professor of Computer Science, Neuroscience, and Pediatrics and Interim Vice President of Research.

This presents a particular challenge for machine learning, which usually relies on spotting consistent patterns in huge amounts of similar data. Thats why personalization is so important.

If we take a cue from a child, we can achieve so much more than just following a script, said Matari. Normal AI approaches fail with autism. AI methods require a lot of similar data and that just isnt possible with autism, where heterogeneity reigns.

The researchers tackled this problem in their analysis of the childrens engagement after the intervention. Computer models of engagement were developed by combining many types of data, including eye gaze and head pose, audio pitch and frequency, and performance on the task.

Making these algorithms work using real-world data presented a major challenge, given the accompanying noise and unpredictability.

This experiment was right in the center of their learning experience, said Kartik, who helped install the robots in the childrens homes.

There were cats jumping on the robot, a blender going off in the kitchen, and people coming in and out of the room. As such, the machine learning algorithms had to be sophisticated enough to focus on pertinent information related to the therapy session and dismiss environmental noise.Improving human-robot interactionAssessments were conducted before and after the month-long interventions. While the researchers expected to see some improvements in participants, the results surpassed their expectations. At the end of the months intervention, 100% of the participants demonstrated improved math skills, while 92% also improved in social skills.

In post-experiment analyses, the researchers were also able to glean some other interesting information from the data that could give us a peek into the recipe for ideal child-robot interactions.

The study observed higher engagement for all participants shortly after the robot had spoken. Specifically, participants were engaged about 70% of the time when the robot had spoken in the previous minute, but less than 50% of the time when the robot had not spoken for more than a minute.

While a personalized model for every user is ideal, the researchers also determined it was possible to achieve adequate results using engagement models trained on data from other users.

Moreover, the study observed caregivers only had to intervene when a child lost interest for a longer period of time. In contrast, participants usually re-engaged by themselves after shorter periods of disinterest. This suggests robotic systems should focus on counteracting longer periods of disengagement.

Mataris lab will continue to study the data gathered from the experiment: One active sub-project involves analyzing and modeling the childrens cognitive-affective states, including emotions such as confusion or excitement. The project, led by progressive degree in computer science student Zhonghao Shi, aims to design affect-aware socially assistive robot tutors that are even more sensitive to the emotions and moods of its users in the context of learning.

The hope is that future studies in this lab and elsewhere can take all the things that weve learned and hopefully design more engaging and personalized human-robot interactions, said Jain.ReferenceJain et al. (2020) Modeling engagement in long-term, in-home socially assistive robot interventions for children with autism spectrum disorders. Science Robotics. DOI: https://doi.org/10.1126/scirobotics.aaz3791

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

See the rest here:
Could This Robot Help Children With Autism Learn? - Technology Networks

New study uncovers the neurology behind how kind and generous you are – Ladders

Virtually every society rests its principles on the basic constructs of good and evil. The tendency presumes that one denotes the absence of the other when the reality actually exists in a clinical gray area.

As concluded by a pioneering new paper published in the February edition ofNature Neuroscience, human ecology is informed by physiological signatures. When the amygdala and the medial prefrontal cortex fail to communicate in sync, instances of anti-social behavior increases.

Social behaviors recruit multiple cognitive operations that require interactions between cortical and subcortical brain regions. Interareal synchrony may facilitate such interactions between cortical and subcortical neural populations, the authors write. These findings suggest that specialized coordination in the medial prefrontalamygdala network underlies social-decision preferences.

The new study was co-authored byOlga Dal Monte,Cheng C. J. Chu,Nicholas A. FaganandSteve W. C. Chang ofYale Universitys department of psychology.

This neurological correlation observed by Dal Monte and her team not only determined the presence of prosocial and antisocial traits, but it also allowed the experts to gauge the extent to which they were present.

The first leg of the research employed non-human primate models. Monkeys were encouraged to choose between sharing fruit juice with another monkey and keeping the sample for themselves over the course of multiple trials. During each scenario, the psychologists would monitor neural activity.

In every trial, a monkeys decision to act benevolently was preluded by the basolateral amygdala and the rostral anterior cingulate gyrus region of their medial prefrontal cortex expressing high synchronization. The exact inverse was evident when the subjects decided to act selfishly.

By merely analyzing the degree of neural suppression andsynchronicitythe authors were able to reliably predict which outcome each primate was about to realize.

We found aunique signature of neural synchrony that reflects whether a prosocial or an antisocial decision was made, senior authorChang, who is an assistant professor of psychology and neuroscience at Yale, said in anews release. We all know there are individual differences in levels ofgenerosity. Maybe Scrooge did not havehigh levels of synchronyafter all.

While lesser primates may not evidence as many genetic similarities to us as the great apes, the researchers suspect their finds to be translatable to human subjects saying nothing of the previously published literature bridging the gap between aggression and neurological deficiencies.

Not unlike the thesis recently motioned by the journal Scientific Reportsback in January the core elements of empathetic behaviors are authored by biological predispositions as opposed to someconditioned moral avatar.

Synchronization between the two nodes was enhanced for a positive other-regarding preference but suppressed for a negative ORP, the authors write. These interactions occurred in beta and gamma frequency bands depending on the area contributing the spikes, exhibited a specific directionality of information flow associated with a positive ORP and could be used to decode social decisions.

The new study, published on February 24th, 2020, is titled Specialized Medial PrefrontalAmygdala Coordination in Other-Regarding Decision Preference.

The report can be read in full in the Journal of Nature Neuroscience.

Originally posted here:
New study uncovers the neurology behind how kind and generous you are - Ladders

Minerva Neurosciences to Host Key Opinion Leader Meeting on Avolition, the Most Central Domain for the Successful Treatment of Negative Symptoms in…

WALTHAM, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat unmet medical needs of central nervous system (CNS) disorders, today announced that it will host a Key Opinion Leader (KOL) breakfast to discuss the importance of improving avolition in the successful treatment of negative symptoms of schizophrenia on Friday, March 6, 2020 in New York.

The event will be hosted by Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva, and will feature a brief presentation and moderated discussion with Philip Harvey, PhD, from the University of Miami Miller School of Medicine, and Greg Strauss, PhD, from the Georgia Psychiatric Risk Evaluation Program. They will discuss Dr. Strausss paper on the central role of avolition, defined as reductions in the desire for and initiation of motivated behavior, in treating negative symptoms in schizophrenia that was published recently in Schizophrenia Bulletin. A Q&A session will be held at the conclusion of the event.

Dr. Strauss will discuss his findings in the context of data from the Phase 2b study of Minervas lead product candidate, Roluperidone (MIN-101), a novel 5-HT2A and receptor antagonist. Roluperidone is currently in a pivotal Phase 3 clinical trial for the treatment of negative symptoms of schizophrenia.

Greg Strauss, PhD directs the Clinical Affective Neuroscience Laboratory and Georgia Psychiatric Risk Evaluation Program (G-PREP). He has authored over 120 publications, and his research has been recognized by several awards, such as the Early Career Award from the National Academy of Neuropsychology, Early Career Award from the American Society for Clinical Psychopharmacology, Wechsler Early Career Award for Innovative Research on Cognition from the American Psychological Foundation, and Young Investigator Awards from the International Congress on Schizophrenia Research and the Schizophrenia International Research Society. He has received over $15M in grants as Principal Investigator or Co-Investigator from the NIMH, NARSAD, VA MIRECC, APF, NSF and G-PREP. He serves on the editorial boards of Schizophrenia Bulletin, Journal of Abnormal Psychology, Clinical Psychological Science, and Schizophrenia Research: Cognition.

Philip D. Harvey, PhD is Leonard M. Miller Professor of Psychiatry and director of the Division of Psychology at the University of Miami Miller School of Medicine and a VA Senior Health Scientist. Dr. Harveys research has focused on cognition and functioning, and he has written extensively on aging in schizophrenia, negative symptoms in schizophrenia, functional impairments in severe mental illness, the cognitive effects of typical and atypical antipsychotics, and the effects of cognitive enhancing agents and cognitive training in various conditions. He is the author of over 1,000 scientific papers and abstracts, and he has written over 60 book chapters. Dr. Harvey is a widely cited author who was repeatedly designated by Thompson-Reuters as being in the top 1% of all researchers in citations in mental health each year since 2010. He has received numerous awards for his research in schizophrenia.

This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited. Members of the media and the public are invited to participate via the live webcast.

About Minerva Neurosciences

Minervas proprietary compounds include: roluperidone (MIN-101), in clinical development for schizophrenia; seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinsons disease. Minervas common stock is listed on the NASDAQ Global Market under the symbol NERV. For more information, please visit http://www.minervaneurosciences.com.

Forward-Looking Safe Harbor Statement

This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, reflect managements expectations as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the timing and scope of future clinical trials and results of clinical trials with roluperidone (MIN-101); the clinical and therapeutic potential of this compound; the timing and outcomes of future interactions with U.S. and foreign regulatory bodies; our ability to successfully develop and commercialize our therapeutic products; the sufficiency of our current cash position to fund our operations; and managements ability to successfully achieve its goals. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether roluperidone will advance further in the clinical trials process and whether and when, if at all, it will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether any of our therapeutic products will be successfully marketed if approved; whether any of our therapeutic product discovery and development efforts will be successful; managements ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; and general economic conditions. These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption Risk Factors in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter endedSeptember 30, 2019, filed with theSecurities and Exchange Commission on November 4, 2019. Copies of reports filed with theSECare posted on our website at http://www.minervaneurosciences.com. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.

Contact:

William B. BoniVP, Investor Relations/Corp. CommunicationsMinerva Neurosciences, Inc.(617) 600-7376

Read more:
Minerva Neurosciences to Host Key Opinion Leader Meeting on Avolition, the Most Central Domain for the Successful Treatment of Negative Symptoms in...